Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes

NCT00660998 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 318

Last updated 2014-12-11

No results posted yet for this study

Summary

Asses efficacy of Vardenafil in patients with type 1 diabetes and erectile dysfunction

Conditions

Interventions

DRUG

Levitra (Vardenafil, BAY38-9456)

5mg, 10mg or 20mg taken 1h before sexual intercourse

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Completion
2004-01-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00660998 on ClinicalTrials.gov